Special report: pharmacogenomics of cancer-candidate genes

BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

The BlueCross BlueShield Association Technology Evaluation Center website (www.bcbs.com/tec) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website.

Citation

Authors' objectives
The objective of this Special Report is to catalog genetic tests and measures of gene activity that are currently under study for pharmacogenomic applications. Pharmacogenomics will be broadly interpreted to include detecting the specific molecular targets of the newer, "targeted" therapies to select patients likely to respond, as well as detecting other pharmacodynamic markers that influence targeted therapy response. Molecular indicators of variability in response or toxicity to standard chemotherapy drugs will also be reviewed. This Report will also provide a more detailed summary of the supporting data for a few illustrative examples. The tests identified in this Report are not comprehensive, but rather reflect the greatest research activity and in most cases are commercially available. Further, only tests developed from candidate genes will be examined; microarray pattern analysis and the development of predictive panels composed of many genetic markers are beyond the scope of this Report.

Project page URL
http://www.bcbs.com/blueresources/tec/contact-tec.html

PubMedID
18080403

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Agents /pharmacology; Biomarkers; Drug Design; Drug Therapy /methods; Genetic Testing; Neoplasms /diagnosis /drug therapy /genetics; Patient-Centered Care; Pharmacogenetics /methods

Language Published
English

Country of organisation
United States

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32010000200
Date abstract record published
24/03/2010